3692.HK

Hansoh Pharmaceutical Group Company Limited [3692.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

3692.HK Stock Summary

In the News

3692.HK Financial details

Company Rating
-
Market Cap
95.19B
Income
5.29B
Revenue
19.43B
Book val./share
-
Cash/share
-
Dividend
0.19
Dividend %
1.38%
Employees
9.12K
Optionable
No
Shortable
Yes
Earnings
26 Mar 2024
P/E
29.21
Forward P/E
-
PEG
3.05
P/S
8.06
P/B
7.59
P/C
-
P/FCF
30.87
Quick Ratio
7.29
Current Ratio
9.86
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.9
EPS next Y
-
EPS next Q
-
EPS this Y
-4.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.92%
Revenue last 5Y
3.97%
Revenue Q/Q
-8.83%
EPS Q/Q
-
-
-
-
-
SMA20
-2.78%
SMA50
-2.78%
SMA100
34.62%
Inst Own
-
Inst Trans
-
ROA
9%
ROE
17%
ROC
0.11%
Gross Margin
91%
Oper. Margin
32%
Profit Margin
28%
Payout
28%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.41-17.24
52W High
+104.59%
52W Low
+286.44%
RSI
43
Rel Volume
0.48
Avg Volume
6.09M
Volume
2.89M
Perf Week
-0.97%
Perf Month
-9.85%
Perf Quarter
42.25%
Perf Half Y
46.75%
-
-
-
-
Beta
0.556
-
-
Volatility
0.77%, 1.25%
Prev Close
1.22%
Price
34.78
Change
-0.8%

3692.HK Financial Performance

3692.HK Dividend History

3692.HK Frequently Asked Questions

What is Hansoh Pharmaceutical Group Company Limited stock symbol ?

Hansoh Pharmaceutical Group Company Limited is a CN stock and trading under the symbol 3692.HK

What is Hansoh Pharmaceutical Group Company Limited stock quote today ?

Hansoh Pharmaceutical Group Company Limited stock price is $34.78 today.

Is Hansoh Pharmaceutical Group Company Limited stock public?

Yes, Hansoh Pharmaceutical Group Company Limited is a publicly traded company.

Something similar

Top by Market Cap
ABEC.DE
CMC.DE
BRK-A
ABEA.DE
AMZ.DE
Same Sector
002737.SZ
2181.HK
PHARM.AS
KALV
TFX
Same Price Range
5525.TW
LANDM
XDWU.L
4989.TW
CENTRALBK.NS
Similar Market Cap
GEC.L
TOELY
8218.T
8237.T
0003.HK

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 6.09M
  • Market Capitalization 95.19B
  • Employee 9.12K
  • CEO Ms. Huijuan Zhong
  • Headquarters Lianyungang,CN
  • IPO Date 2019-06-14
  • Website https://www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.